A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme
Latest Information Update: 07 Sep 2023
At a glance
- Drugs Follitropin delta (Primary) ; Follitropin alfa
- Indications Female infertility
- Focus Pharmacodynamics; Registrational
- Acronyms ESTHER-2
- Sponsors Ferring Pharmaceuticals
- 29 Jun 2021 Results published in the Ferring Pharmaceuticals Media Release.
- 29 Jun 2021 According to a Ferring Pharmaceuticals media release, data from this study were presented today at the 37th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE).
- 10 Oct 2018 Results of a pooled analysis assessing the neonatal outcome and incidence of congenital malformations following treatment with follitropin delta in phase III studies (ESTHER-1 and -2) presented at the American Society for Reproductive Medicine Scientific Congress 2018